Onconic Therapeutics (476060.KQ) — Stock Score Summary

Onconic Therapeutics (476060.KQ) has a MoatMap StockRank of 66/100 based on Quality (87/100), Value (16/100), and Momentum (47/100) factor scores. The current signal is BUY.

Onconic Therapeutics Inc. engages in the research and development of anti-cancer therapy in South Korea.

Key Financial Metrics

Price$10.44
Market Cap$454M
P/E (TTM)44.18
Price/Book9.79
Return on Equity29.5%
Return on Invested Capital19.1%
Debt/Equity0.14
Gross Margin100.0%
Operating Margin20.0%
Revenue Growth150.6%
Free Cash Flow$2K

Onconic Therapeutics operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (South Korea).

Frequently Asked Questions

What is Onconic Therapeutics’s (476060.KQ) StockRank?
MoatMap’s StockRank for Onconic Therapeutics (476060.KQ) is 66/100, with a Buy signal. It is a composite of Quality (87), Value (16), and Momentum (47) factor ranks across MoatMap’s 19,000+ stock universe.
Does Onconic Therapeutics have an economic moat?
Onconic Therapeutics (476060.KQ) has a Quality factor score of 87/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Onconic Therapeutics a buy, hold, or sell?
MoatMap’s current signal for Onconic Therapeutics (476060.KQ) is Buy, based on a StockRank of 66/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Onconic Therapeutics in?
Onconic Therapeutics (476060.KQ) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (South Korea).
Browse all ranked stocks476060.KQ deep dive reportAI ChampionsHow we score stocksSense-check another stock